Androgen Deprivation Therapy, External Beam Radiotherapy and Stereotactic Radiosurgery Boost for Prostate Cancer — ADEBAR

Neoplasm, Prostate Clinical Trial

Official title:
Androgen Deprivation Therapy, External Beam Radiotherapy and Stereotactic Radiosurgery Boost for Men With Intermediate- or High-risk Prostate Cancer

Status Completed

Clinical Trial Summary

For the treatment for intermediate- and high-risk prostate cancer, Cyberknife boost will be used after 4 weeks of intensity modulated radiotherapy to pelvis. The boost doses are 18 Gy and 21 Gy in 3 fractions, respectively. The investigators plan to evaluate the toxicity of two dose groups and decide the appropriate dose for Cyberknife boost. Also, PSA control will be evaluated.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT03322020
Study type	Interventional
Source	Asan Medical Center
Contact
Status	Completed
Phase	Phase 1/Phase 2
Start date	March 21, 2016
Completion date	June 30, 2019

View Details

See also
Status	Clinical Trial	Phase
Active, not recruiting	`NCT03344757` - Health Gatherings - For Your Health After Cancer	N/A
Active, not recruiting	`NCT03149861` - Detection of Clinically Significant Prostate Cancer With 18F-DCFPyL PET/MR	N/A
Not yet recruiting	`NCT05422911` - Abiraterone, Enzalutamide, or Apalutamide in Castrate-sensitive Prostate Cancer.	Phase 2
Completed	`NCT01553188` - AMG 386 and Abiraterone for Advanced Prostate Cancer	Phase 2
Completed	`NCT01819285` - Early Compared With Delayed Hormone Therapy in Treating Patients With Nonmetastatic Prostate Cancer	Phase 3